References
- Buch A, Maroni B, Hartman C. (2015). Dose exposure relationship of vadadustat is independent of the level of renal function. American Society of Nephrology Kidney Week Annual Meeting; 2015 Nov 3–8; San Diego, CA, USA (Abstract Program #SA-PO537)
- Coca SG, Singanamala S, Parikh CR. (2012). Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 81:442–8
- Cody JD, Hodson EM. (2016). Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis. Cochrane Database Syst Rev 2016:CD003266
- Collister D, Ferguson T, Komenda P, Tangri N. (2016). The patterns, risk factors, and prediction of progression in chronic kidney disease: a narrative review. Semin Nephrol 36:273–82
- D’Angelo G. (2013). Role of hepcidin in the pathophysiology and diagnosis of anemia. Blood Res 48:10–5
- Dixon J, Lane K, MacPhee J, Philips B. (2014). Xenobiotic metabolism: the effect of acute kidney injury on non-renal drug clearance and hepatic drug metabolism. Int J Mol Sci 15:2538–53
- Heifets M, Davis TA, Tegtmeyer E, Klahr S. (1987). Exercise training ameliorates progressive renal disease in rats with five-sixth nephrectomy. Kidney Int 32:815–20
- Heyman SN, Rosenberger C, Rosen S. (2011). Acute kidney injury: lessons from experimental models. Contrib Nephrol 169:286–96
- Izuwa Y, Kusaba JI, Horiuchi M, et al. (2009). Comparative study of increased plasma quinidine concentration in rats with glycerol and cisplatin-induced acute renal failure. Drug Metab Pharmacokinet 24:451–7
- Jain MR, Joharapurkar AA, Pandya V, et al. (2016). PharmacologicalcCharacterization of ZYAN1, a novel prolyl hydroxylase inhibitor for the treatment of anemia. Drug Res (Stuttg) 66:107–12
- Kane-Gill SL, Goldstein SL. (2015). Drug-induced acute kidney injury: a focus on risk assessment for prevention. Crit Care Clin 31:675–84
- Kielstein JT, Salpeter SR, Bode-Boeger SM, et al. (2006). Symmetric dimethylarginine (SDMA) as endogenous marker of renal function—a meta-analysis. Nephrol Dial Transplant 21:2446–51
- Koulouridis I, Alfayez M, Trikalinos TA, et al. (2013). Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis 61:44–56
- Ladda MA, Goralski KB. (2016). The effects of CKD on cytochrome P450-mediated drug metabolism. Adv Chronic Kidney Dis 23:67–75
- Lalande L, Charpiat B, Leboucher G, Tod M. (2014). Consequences of renal failure on non-renal clearance of drugs. Clin Pharmacokinet 53:521–32
- Lane BR, Demirjian S, Derweesh IH, et al. (2014). Is all chronic kidney disease created equal? Curr Opin Urol 24:127–34
- Ozkok A, Edelstein CL. (2014). Pathophysiology of cisplatin-induced acute kidney injury. Biomed Res Int 2014:967826
- Panwar B, Gutiérrez OM. (2016). Disorders of iron metabolism and anemia in chronic kidney disease. Semin Nephrol 36:252–61
- Peres LA, Cunha Júnior AD. (2013). Acute nephrotoxicity of cisplatin: molecular mechanisms. J Bras Nefrol 35:332–40
- Philips BJ, Lane K, Dixon J, Macphee I. (2014). The effects of acute renal failure on drug metabolism. Expert Opin Drug Metab Toxicol 10:11–23
- Srinivas NR. (2010). Altered disposition of drugs in acute renal failure rat models: drug development strategies and perspectives. Arzneimittelforsch 60:731–48
- Stiles KP, Moffatt MJ, Agodoa LY, et al. (2003). Renal cell carcinoma as a cause of end-stage renal disease in the United States: patient characteristics and survival. Kidney Int 64:247–53
- Tajima N, Soma M, Ishizuka H, et al. (2005). Quantitative evaluation of effect of renal failure on the pharmacokinetics of panipenem in rats. Biol Pharm Bull 28:2170–2
- Thomson BK, Nolin TD, Velenosi TJ, et al. (2015). Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms. Am J Kidney Dis 65:574–82
- Vestergaard B, Agersø H, Lykkesfeldt J. (2013). Nephrectomized and hepatectomized animal models as tools in preclinical pharmacokinetics. Basic Clin Pharmacol Toxicol 113:75–86
- Vilay AM, Churchwell MD, Mueller BA. (2008). Clinical review: drug metabolism and nonrenal clearance in acute kidney injury. Crit Care 12:235. doi:10.1186/cc7093
- Wang YM, Sloey B, Wong T, et al. (2011). Investigation of the pharmacokinetics of romiplostim in rodents with a focus on the clearance mechanism. Pharm Res 28:1931–8
- Zhang Y, Kompa AR. (2014). A practical guide to five-sixth nephrectomy in the rat with subsequent methodology for assessing renal and cardiac function. Nephrol 19:552–61